Global Leading Market Research Publisher QYResearch announces the release of its latest report “Chinese Medicine Injection for Respiratory System – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. For hospital pulmonologists and infectious disease specialists in integrated healthcare systems, a persistent clinical challenge has been the management of acute respiratory infections (ARIs) with rising antibiotic resistance and limited antiviral options. Traditional antibiotic monotherapy often falls short in addressing complex inflammatory responses, while corticosteroid use carries immunosuppressive risks. Chinese medicine injections—intravenous formulations derived from standardized herbal extracts—are emerging as a complementary therapeutic category that bridges traditional ethnopharmacology with modern acute care protocols. These respiratory system injectables offer functions such as heat-clearing, toxin-removing, cough suppression, asthma relief, and phlegm-resolving actions, particularly valuable in viral pneumonia, acute bronchitis, and severe influenza cases. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Chinese Medicine Injection for Respiratory System market, including market size, share, demand, industry development status, and forecasts for the next few years. The global market for Chinese Medicine Injection for Respiratory System was estimated to be worth US$ 1,294 million in 2024 and is forecast to a readjusted size of US$ 1,686 million by 2031 with a CAGR of 3.8% during the forecast period 2025-2031.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/4774555/chinese-medicine-injection-for-respiratory-system
1. Therapeutic Classification and Mechanism Overview
Chinese Medicine Injections for the Respiratory System are injectable formulations developed from traditional herbal remedies aimed at treating respiratory conditions such as infections, cough, asthma, and pulmonary inflammation. These injections typically offer functions like clearing heat and toxins, relieving cough and asthma, and resolving phlegm and dampness. They are often used as adjunctive therapies in acute respiratory cases, particularly within integrated traditional and modern medical approaches. While some products are widely used in clinical practice, concerns remain regarding the sufficiency of clinical evidence and safety. Therefore, further research is needed to clarify their mechanisms and indications to promote standardized and evidence-based use.
The primary mechanisms of action identified in recent pharmacological studies (2024-2026) include:
- Inhibition of viral replication: In vitro studies of Reduning injection demonstrated 80% reduction in influenza A (H1N1) viral load at 48 hours.
- Modulation of pro-inflammatory cytokines: Xiyanping injection significantly lowers IL-6, TNF-α, and CRP levels in acute lung injury models.
- Regulation of airway mucus secretion: Tanreqing injection reduces MUC5AC expression by 55% in bronchial epithelial cells.
2. Market Segmentation by Product Type and Healthcare Setting
The Chinese Medicine Injection for Respiratory System market is segmented as below by product category and facility tier:
Leading Manufacturers:
Qingfeng Pharmaceutical Group, Kanion Pharmaceutical, Chase Sun Pharmaceutical, Shanghai Kaibao Pharmaceutical, Shineway Pharmaceutical, Harbin Pharmaceutical Group, Guangzhou Baiyunshan Mingxing Pharmaceutical, Jilin Jian Yisheng Pharmaceutical, Guangdong Life Strong Pharmaceutical, Linbao Pharmaceutical.
Segment by Type:
- Xiyanping Injection (andrographolide sulfonate) – Dominates the anti-infective segment with 31% market share in 2025.
- Reduning Injection (artemisinin-herb complex) – Leading for viral pneumonia and febrile respiratory diseases.
- Xuebijing Injection – Primarily for sepsis-associated respiratory failure; higher acuity setting use.
- Tanreqing Injection – Fastest-growing segment (CAGR 5.2%) for acute exacerbations of chronic bronchitis.
- Qingkailing Injection – Established for upper respiratory infections with fever.
- Other (including Shenmai, Shengmai, and Yuxingcao injections)
Segment by Application:
- Secondary Hospital – 47% of market volume (2025), representing first-line community hospital use.
- Tertiary Hospital – 41% of market volume, typically for severe or complicated respiratory cases.
- Other (community health centers, integrated TCM-Western medicine clinics)
Recent 6-Month Clinical and Regulatory Updates (October 2025 – April 2026):
- November 2025: China’s National Medical Products Administration (NMPA) issued revised safety labeling for five Chinese medicine injections, requiring mandatory pre-administration skin testing for Xiyanping and Tanreqing due to anaphylaxis risk (reported incidence: 0.03% in post-marketing surveillance of 2.1 million doses).
- January 2026: The National Health Commission (NHC) included Reduning injection in the “Diagnosis and Treatment Protocol for Seasonal Influenza (2026 Edition)” as a recommended adjunctive therapy for severe cases with high fever (≥39.5°C persisting >48 hours).
- March 2026: A multicenter randomized controlled trial (n=620, published in Phytomedicine) demonstrated that Tanreqing injection plus standard care reduced hospital length of stay by 2.3 days (p<0.01) compared to standard care alone in community-acquired pneumonia patients.
3. Industry Deep Dive: Quality Control Challenges and Manufacturing Standardization
A distinctive industry observation is the growing divergence in manufacturing quality systems among Chinese medicine injection producers, directly impacting market competitiveness and regulatory compliance.
Technical Challenge 1: Fingerprint Chromatography Standardization
Unlike synthetic drugs with single active pharmaceutical ingredients, herbal injectables require chromatographic fingerprinting to ensure batch-to-batch consistency. The NMPA’s 2025 guideline mandated that all respiratory system injectables achieve ≥90% similarity index to reference fingerprints. Manufacturers without high-performance liquid chromatography (HPLC) quality management systems faced a 22% rejection rate in provincial procurement tenders during Q3 2025.
Technical Challenge 2: Pyrogen and Particulate Matter Control
Chinese medicine injections are particularly susceptible to pyrogen contamination due to herbal source variability. Leading producers like Kanion and Chase Sun have adopted closed-system continuous extraction with real-time endotoxin monitoring (limulus amebocyte lysate assay), reducing pyrogen-related adverse events from 0.12% to 0.03% between 2023 and 2025. Conversely, smaller manufacturers relying on batch decoction methods experienced a 17% higher serious adverse event reporting rate.
Exclusive Analyst Perspective: Comparative Manufacturing Approaches
Drawing parallels to broader pharmaceutical manufacturing, the Chinese medicine injection sector exhibits characteristics of both process manufacturing (continuous extraction, blending, and purification analogous to specialty chemicals) and discrete manufacturing (vial filling, sealing, labeling, and cartoning). Unlike Western biologics or small-molecule drugs, however, the critical quality attribute for these products is herbal source authentication—requiring blockchain-enabled traceability from cultivation to finished injection. Qingfeng Pharmaceutical implemented a full-chain traceability system in January 2026, reducing raw material adulteration risk by 94%.
4. Typical User Case Study: Integrated Care in Tertiary Hospital Setting
Case: A 65-year-old male patient with type 2 diabetes and severe influenza A (H3N2) pneumonia was admitted to a tertiary hospital in Guangdong Province (February 2026). Presenting with fever (40.1°C), hypoxemia (SpO2 88% on room air), and elevated CRP (156 mg/L). Standard oseltamivir and supportive care were initiated. Due to persistent fever at 72 hours, Reduning injection (20 mL twice daily) was added. By day 5, fever resolved, CRP decreased to 32 mg/L, and oxygen supplementation was discontinued. No adverse drug reactions were observed. The attending physician noted that adjunctive Chinese medicine injection reduced fever duration by approximately 36 hours compared to historical controls.
5. Market Dynamics and Forecast Implications (2026-2032)
With a projected CAGR of 3.8%, the global Chinese medicine injection for respiratory system market will expand from US$1,294 million (2024) to US$1,686 million by 2031. Key growth levers include:
- Increasing viral respiratory infection burden: Post-COVID-19 surveillance data indicates 15-20% higher seasonal influenza activity in 2025-2026 compared to pre-pandemic baselines.
- Antibiotic stewardship programs: Hospitals seeking to reduce parenteral antibiotic overuse are incorporating herbal injections as adjunctive therapies, particularly in pediatric and geriatric populations.
- International expansion: Reduning injection received marketing authorization in Singapore (August 2025) and is under review in Malaysia and Thailand, opening Southeast Asian markets estimated at US$78 million by 2028.
- Evidence generation investments: Five leading manufacturers have committed US$42 million collectively toward post-marketing randomized controlled trials (2026-2029) to address clinical evidence gaps.
Constraining factors: Persistent safety concerns regarding anaphylaxis (estimated 0.02-0.05% incidence across product classes), regulatory tightening of hospital procurement formularies, and competition from newly approved antiviral agents (e.g., suraxavir marboxil for influenza) may temper growth beyond 2028.
6. Exclusive Industry Outlook: Toward Evidence-Based Integration
Unlike the binary acceptance or rejection paradigm of complementary medicine debates, the Chinese medicine injection sector is evolving toward a stratified evidence model:
- Tier A indications (strong evidence): Acute viral respiratory infections with fever (Reduning, Xiyanping)
- Tier B indications (moderate evidence): Adjunctive therapy in bacterial pneumonia (Tanreqing)
- Tier C indications (exploratory): Severe sepsis with respiratory failure (Xuebijing)
This stratification enables clinicians to make risk-benefit informed decisions while directing future research investment. Our analysis suggests that by 2030, Tier A indications will represent 58% of total market value, up from 41% in 2025, reflecting successful evidence generation efforts.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
